MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharp, S. Y.
Right arrow Articles by Workman, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharp, S. Y.
Right arrow Articles by Workman, P.

Vol. 58, Issue 5, 1146-1155, November 2000

Establishment of an Isogenic Human Colon Tumor Model for NQO1 Gene Expression: Application to Investigate the Role of DT-Diaphorase in Bioreductive Drug Activation In Vitro and In Vivo

Swee Y. Sharp, Lloyd R. Kelland, Melanie R. Valenti, Lisa A. Brunton, Steve Hobbs, and Paul Workman

CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom

Many tumors overexpress the NQO1 gene, which encodes DT-diaphorase (NADPH:quinone oxidoreductase; EC 1.6.99.2). This obligate two-electron reductase deactivates toxins and activates bioreductive anticancer drugs. We describe the establishment of an isogenic human tumor cell model for DT-diaphorase expression. An expression vector was used in which the human elongation factor 1alpha promoter produces a bicistronic message containing the genes for human NQO1 and puromycin resistance. This was transfected into the human colon BE tumor line, which has a disabling point mutation in NQO1. Two clones, BE2 and BE5, were selected that were shown by immunoblotting and enzyme activity to stably express high levels of DT-diaphorase. Drug response was determined using 96-h exposures compared with the BE vector control. Functional validation of the isogenic model was provided by the much greater sensitivity of the NQO1-transfected cells to the known DT-diaphorase substrates and bioreductive agents streptonigrin (113- to 132-fold) and indoloquinone EO9 (17- to 25-fold) and the inhibition of this potentiation by the DT-diaphorase inhibitor dicoumarol. A lower degree of potentiation was seen with the clinically used agent mitomycin C (6- to 7-fold) and the EO9 analogs, EO7 and EO2, that are poorer substrates for DT-diaphorase (5- to 8-fold and 2- to 3-fold potentiation, respectively), and there was no potentiation or protection with menadione and tirapazamine. Exposure time-dependent potentiation was seen with the diaziquone analogs methyl-diaziquone and RH1 [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone], the latter being an agent in preclinical development. In contrast to the in vitro potentiation, there was no difference in the response to mitomycin C when BE2 and BE vector control were treated as tumor xenografts in vivo. This isogenic model should be valuable for mechanistic studies and bioreductive drug development.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. A. Eccles, A. Massey, F. I. Raynaud, S. Y. Sharp, G. Box, M. Valenti, L. Patterson, A. de Haven Brandon, S. Gowan, F. Boxall, et al.
NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
Cancer Res., April 15, 2008; 68(8): 2850 - 2860.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Volpato, N. Abou-Zeid, R. W. Tanner, L. T. Glassbrook, J. Taylor, I. Stratford, P. M. Loadman, M. Jaffar, and R. M. Phillips
Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system
Mol. Cancer Ther., December 1, 2007; 6(12): 3122 - 3130.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Y. Sharp, C. Prodromou, K. Boxall, M. V. Powers, J. L. Holmes, G. Box, T. P. Matthews, K.-M. J. Cheung, A. Kalusa, K. James, et al.
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Mol. Cancer Ther., April 1, 2007; 6(4): 1198 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Y. Sharp, K. Boxall, M. Rowlands, C. Prodromou, S. M. Roe, A. Maloney, M. Powers, P. A. Clarke, G. Box, S. Sanderson, et al.
In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors
Cancer Res., March 1, 2007; 67(5): 2206 - 2216.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Jamieson, K. Wilson, S. Pridgeon, J. P. Margetts, R. J. Edmondson, H. Y. Leung, R. Knox, and A. V. Boddy
NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism
Clin. Cancer Res., March 1, 2007; 13(5): 1584 - 1590.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. V Powers and P. Workman
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S125 - S135.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. M.S. Al-Saffar, H. Troy, A. R. de Molina, L. E. Jackson, B. Madhu, J. R. Griffiths, M. O. Leach, P. Workman, J. C. Lacal, I. R. Judson, et al.
Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Choline Kinase Inhibitor MN58b in Human Carcinoma Models
Cancer Res., January 1, 2006; 66(1): 427 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. da Rocha Dias, F. Friedlos, Y. Light, C. Springer, P. Workman, and R. Marais
Activated B-RAF Is an Hsp90 Client Protein That Is Targeted by the Anticancer Drug 17-Allylamino-17-Demethoxygeldanamycin
Cancer Res., December 1, 2005; 65(23): 10686 - 10691.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. H. Ward, S. Danson, A. T. McGown, M. Ranson, N. A. Coe, G. C. Jayson, J. Cummings, R. H.J. Hargreaves, and J. Butler
Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone
Clin. Cancer Res., April 1, 2005; 11(7): 2695 - 2701.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
P. WORKMAN
Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics
Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 499 - 515.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
D. L. Dehn, S. L. Winski, and D. Ross
Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones: Evaluation of the Activity of RH1
Clin. Cancer Res., May 1, 2004; 10(9): 3147 - 3155.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. L. Cowen, A. V. Patterson, B. A. Telfer, R. E. Airley, S. Hobbs, R. M. Phillips, M. Jaffar, I. J. Stratford, and K. J. Williams
Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts
Mol. Cancer Ther., September 1, 2003; 2(9): 901 - 909.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics